Cargando…
A biomaterials viewpoint for the 2020 SARS-CoV-2 vaccine development
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused a considerable loss of life, morbidity, and economic distress since its emergence in late 2019. In response to the novel virus, public and private institutions around the world have utilized novel technologies to de...
Autores principales: | Jatoi, Isak, Fan, Jingyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chinese Medical Multimedia Press Co., Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255824/ https://www.ncbi.nlm.nih.gov/pubmed/35837251 http://dx.doi.org/10.3877/cma.j.issn.2096-112X.2021.01.005 |
Ejemplares similares
-
EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs
por: Bijlsma, Johannes WJ
Publicado: (2021) -
The 2020 race towards SARS-CoV-2 specific vaccines
por: Karpiński, Tomasz M., et al.
Publicado: (2021) -
The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development
por: Alturki, Sana O., et al.
Publicado: (2020) -
Development of vaccines for SARS-CoV-2
por: Ng, Wern Hann, et al.
Publicado: (2020) -
SARS-CoV-2 virus: Vaccines in development
por: Huang, Qingrui, et al.
Publicado: (2021)